No quarterly revenue total was found in BIOVIE INC.'s SEC filings.
Biovie Inc. (BIVI) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $9.0 million in cash and investments and $275,430 in total debt.
Revenue
—
Net income
$-5.65M
-61.8% vs year-ago quarter
Operating cash flow
$-4.12M
+26.5% vs year-ago quarter
Free cash flow
—
EPS
$-0.71
+62.1% vs year-ago quarter
Dividend per share
None
Shares outstanding
7.54M
+0.1% vs year-ago quarter
Net cash
$8.70M
Q4 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BIVI (Nasdaq), BIVIW (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- NV
- Headquarters
- Carson City, NV
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1580149
- Former names
- NANOANTIBIOTICS, INC. (until Jul 22, 2016)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2026 Jun 30, 2026 |
Q3 FY2026 Mar 31, 2026 |
Q2 FY2026 Dec 31, 2025 |
Q1 FY2026 Sep 30, 2025 |
Q4 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$5.7M | -$5.4M | -$6.3M | -$5.3M | -$3.7M |
| Net income | -$5.6M | -$5.3M | -$6.1M | -$5.1M | -$3.5M |
| Diluted EPS | -$0.71 | -$0.70 | -$0.77 | -$0.98 | -$1.88 |
| Operating cash flow | -$4.1M | -$7.4M | -$4.4M | -$3.0M | -$5.6M |
| Total assets | $14.3M | $17.5M | $22.5M | $26.8M | $21.6M |
| Total liabilities | $4.0M | $1.9M | $3.2M | $1.9M | $2.6M |
| Stockholders' equity | $10.3M | $15.6M | $19.3M | $24.9M | $19.0M |
| Cash and investments | $9.0M | $13.1M | $20.5M | $25.0M | $17.5M |
| Total debt | $275,430 | $295,717 | $314,915 | $332,730 | $349,894 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Sep 14, 2026 | Sep 11, 2026 |
| 10-K | Annual report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 10-Q | Quarterly report | Feb 6, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change
|
Nov 13, 2025 | Nov 10, 2025 |
All 507 Biovie Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.